Charles River Laboratories International saw the highest growth of 399% in patent filings in October and 199% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 399% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Charles River Laboratories International‘s patent filings and grants. Buy the databook here.
Charles River Laboratories International has been focused on protecting inventions in United States(US) with five publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 25% filings and 100% grants. The United States(US), European Patent Office(EPO), China(CN), and Denmark(DK) patent Office are among the top ten patent offices where Charles River Laboratories International is filings its patents. Among the top granted patent authorities, Charles River Laboratories International has 100% of its grants in United States(US)
Johnson & Johnson could be the strongest competitor for Charles River Laboratories International
See Also:
Housing equipment & aviary systems related patents lead Charles River Laboratories International portfolio followed by diabetic macular edema, and cough
Charles River Laboratories International has highest number of patents in housing equipment & aviary systems followed by diabetic macular edema, cough, asthma, and idiopathic pulmonary fibrosis.
For comprehensive analysis of Charles River Laboratories International's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.